Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 457,500 shares, an increase of 90.3% from the December 31st total of 240,400 shares. Approximately 3.2% of the company’s shares are sold short. Based on an average daily volume of 3,640,000 shares, the days-to-cover ratio is presently 0.1 days.

Virpax Pharmaceuticals Price Performance

NASDAQ:VRPX traded up $0.01 on Wednesday, reaching $0.30. 110,516 shares of the company’s stock were exchanged, compared to its average volume of 437,565. The stock has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.68. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48.

Wall Street Analyst Weigh In

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. 32.23% of the stock is currently owned by hedge funds and other institutional investors.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.